The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment
Abstract
This study, conducted in three separate outpatient health care delivery settings, examined the therapeutic expectations of patients with multiple sclerosis (MS) before they initiated interferon beta-lb therapy, the results of current educational procedures to correct unrealistic expectations, and the relationship between post-education expectations and discontinuing therapy. Ninety-nine consecutive patients were seen in a university based outpatient MS clinic, an academic group practice outpatient MS clinic, or a health maintenance organization outpatient neurology clinic Before the educational sessions, 57% of the patients expressed unrealistically optimistic expectations regarding reduction in attack rate and 34% expressed unrealistically optimistic expectations regarding improvement in functional status. Educational procedures significantly altered unrealistic expectations but the results were sub-optimal since 33% of the patients maintained overly optimistic expectations regarding reduction in attack rate. Post-education unrealistic expectations of improvement in functional status were significantly related to discontinuing therapy within 6 months. Three adverse effects of therapy also were related independently to adherence to treatment depression and flu-like symptoms were related to discontinuing therapy while soreness at injection site was related to continuing therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, depression has been found to be related to neurological changes in the brain due to the demyelination process [20], treatment adherence to medical advice and treatments [21], immune functioning [22] and MS disease exacerbation [23].”
Citations
Cites
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. Μ., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,446
Self-citationInterferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,964
(1980) · Postgraduate Medical Journal · doi:10.1136/pgmj.56.657.530 · Cited by 1,829
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
Johnson, K., Brooks, B., Cohen, J. A., Ford, C., Goldstein, J., Lisak, R., Myers, L., Panitch, H., Rose, J., Schiffer, R., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,667
Adherence to Medication Regimens: Updating a Complex Medical Issue
O'brien, M. K., Petrie, K., & Raeburn, J. (1992) · Medical Care Review · doi:10.1177/002570879204900403 · Cited by 202
Goodkin, D. E. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91713-2 · Cited by 41
Self-citationInterferon beta treatment for multiple sclerosis: persisting questions
Goodkin, D. E. (1996) · Multiple Sclerosis Journal · doi:10.1177/135245859600100605 · Cited by 15
Self-citation
Research works printed but not linked: 2
- Neilley LK, 1995, Neurology, 45, A437
- Mohr DC, 1995, Neurology, 45
Cited by
Sorted by citations
Items 101–133 of 133
Noncompliance with treatment of neurologic disease
Nicholl, J. S. (2002) · Current Treatment Options in Neurology · doi:10.1007/s11940-002-0014-4 · Cited by 7
Psychiatric Disorders, Stress, and Their Treatment Among People with Multiple Sclerosis
Mohr, D. C. (2011) · Springer eBooks · doi:10.1007/978-1-4419-0029-6_8 · Cited by 6
Self-citationJernas, Ł., Wencel, J., Wiak, A., Bieniek, M., & Bartosik-Psujek, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157950 · Cited by 6
Braune, S., Stühler, E., Heer, Y., van Hövell, P., Bergmann, A., & NeuroTransData Study Group (2022) · Frontiers in Digital Health · doi:10.3389/fdgth.2022.856829 · Cited by 5
Depression and Multiple Sclerosis
Serafin, D., Weisbrot, D., & Ettinger, A. (2012) · Wiley eBooks · doi:10.1002/9781118348093.ch13 · Cited by 4
Rahn, A. C., Riemann-Lorenz, K., Alegiani, A. C., Pust, G. E. A., van de Roemer, A., Schmitz, L., Vettorazzi, E., Köpke, S., & Heesen, C. (2020) · Patient Education and Counseling · doi:10.1016/j.pec.2020.09.035 · Cited by 4
Cordioli, C., Callari, G., Fantozzi, R., Caruso, F., Martucci, G., Mascara, S., & Zipoli, V. (2021) · Neurological Sciences · doi:10.1007/s10072-020-04969-3 · Cited by 4
Sriwastava, S., Beard, K., Amatya, S., Shrestha, K., Jaiswal, S., & Lisak, R. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95343-6.00014-5 · Cited by 3
Genç, G., Demirkaya, Ş., Bek, S., & Odabaşı, Z. (2016) · Nöro Psikiyatri Arşivi · doi:10.5152/npa.2016.12621 · Cited by 3
Ala, S., Amirkafi, A., Kohandel, K., Shahmohammadi, S., & Sahraian, M. A. (2024) · BMC Neurology · doi:10.1186/s12883-024-03765-2 · Cited by 3
Adherence to First-Line Disease-Modifying Therapy for Multiple Sclerosis in Kuwait
Alroughani, R., & Thussu, A. (2012) · International Journal of MS Care · doi:10.7224/1537-2073-14.1.17 · Cited by 3
Chen, S., Guo, X., & Ju, X. (2018) · Lecture notes in computer science · doi:10.1007/978-3-030-03649-2_3 · Cited by 3
Smith, E. C., & Langdon, D. W. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00806-x · Cited by 2
Clinical and experimental data on the use of laquinimod for the treatment of multiple sclerosis
Lee, D.-H., & Linker, R. A. (2012) · Clinical Investigation · doi:10.4155/cli.12.66 · Cited by 2
Brunetti, L., & Hunter, S. F. (2014) · PubMed · Cited by 2
Efeitos adversos no tratamento da Esclerose Múltipla com drogas imunomoduladoras
Tilbery, C. P., Fazzito, M. M., Jordy, S. S., Thomaz, R. B., & Fernandes, I. R. (2019) · Revista Neurociências · doi:10.34024/rnc.2009.v17.8545 · Cited by 2
Neuropsychiatric Disorders in Multiple Sclerosis
Mohr, D. C., & Cox, D. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-960-8_15 · Cited by 2
Self-citationKiropoulos, L., Kilpatrick, T., Kalincik, T., Churilov, L., McDonald, E., Wijeratne, T., Threader, J., Rozenblat, V., O’Brien-Simpson, N., Van Der Walt, A., et al. (2020) · Trials · doi:10.1186/s13063-020-04261-x · Cited by 2
Alschuler, K. N., Turner, A. P., & Ehde, D. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-34034-0_16 · Cited by 1
Design Issues for Clinical Research in Health Psychology
Schwartz, C. E. (1998) · Comprehensive Clinical Psychology · doi:10.1016/b0080-4270(73)00083-3 · Cited by 1
Management of complex symptoms in multiple sclerosis (MS)
Williams, K. (2015) · doi:10.13140/rg.2.1.3680.8165 · Cited by 1
Steigerung der Therapietreue durch niederschwellige Kontakte
Lang, M., Cepek, L., Rau, D., Denkinger, N., Behrens, K., & Kornhuber, A. W. (2022) · Nervenheilkunde · doi:10.1055/a-1772-0284 · Cited by 1
Aspetti che influenzano l’adesione alla terapia
Patti, F., & Cilia, S. (2012) · Springer eBooks · doi:10.1007/978-88-470-2724-4_8
Interferon-Beta-1a subkutan in der Behandlung der Multiplen Sklerose
Fertl, E., & Krichmayr, M. (2008) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-008-0510-6
Gestione di speranze e aspettative delle terapie farmacologiche
Borghi, M. (2012) · Springer eBooks · doi:10.1007/978-88-470-2724-4_6
Nemr, A. A. K. (2013) · The Egyptian Journal of Hospital Medicine · doi:10.12816/ejhm.2013.16073
Biopsychosocial Comparison of Adherent and Nonadherent Multiple Sclerosis Patients
Glusman, M. B. (2016) · MOspace Institutional Repository (University of Missouri)
Effectiveness of Copaxone in patients with relapsing-remitting multiple sclerosis
Alifirova, V. M., Titova, M. A., & Vereschaka, A. A. (2010) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2010-4-19-22
Cheong, W. L. (2017) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1307
Grignoli, N., Lampropoulos, D., Demuth, C., & Carral, M. D. R. (2026) · Journal of Health Psychology · doi:10.1177/13591053251403264
Multiple sclerosis, disease-modifying treatments and behavioral change
Feinstein, A. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511543760.012
Metadata
- Authors
- Mohr, D. C., Goodkin, D. E., Likosk, W., Gatto, N., Neilley, L. K., Griffin, C., & Stiebling, B.
- Affiliations
- University of California, San Francisco (US)
- Kaiser Permanente (US)
- Cleveland Clinic (US)
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 1996-12
- Volume
- 2
- Issue
- 5
- Pages
- 222-226
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W1563651942
- Cited by
- 131
- References
- 9
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 13 · 2015: 3 · 2014: 6 · 2013: 2 · 2012: 7
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Multiple Sclerosis Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Health Professions › General Health Professions › Patient-Provider Communication in Healthcare
- Keywords
- multiple sclerosis, interferon beta-1b, treatment expectations, medication adherence, patient education, treatment discontinuation, attack rate, functional status, adverse effects, depression, flu-like symptoms
- MeSH terms
- Interferon beta-1a, Interferon beta-1b, Adjuvants, Immunologic, Attitude to Health, Female, Humans, Male, Multiple Sclerosis, Patient Compliance, Patient Dropouts, Patient Education as Topic, Interferon-beta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
